{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:52:08Z","timestamp":1790092328710,"version":"4.0.1"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>X-linked lymphoproliferative disease (XLP), also known as Duncan\u2019s disease, is a primary immunodeficiency disorder linked to the X chromosome. In 1998, SH2D1A, which encodes the signaling lymphocyte activation molecule (SLAM)-associated protein (SAP), was identified as the first pathogenic gene associated with XLP. To date, more than 100 mutation sites in this gene have been documented. The disease is associated with infection with Epstein-Barr virus (EBV) and characterized by hemophagocytic lymphohistiocytosis (HLH), hypogammaglobulinemia, and lymphomas. Pathogenesis is intricately associated with cell type-specific SAP-SLAM signaling pathways. Particularly, the immune cell defects involve impaired T cell-B cell interactions, reduced cytotoxicity of Natural Killer (NK) cells, and abnormal development of Natural Killer T (NKT) cells. These factors collectively increase susceptibility to EBV and drive clinical manifestations in XLP type 1 (XLP1) patients. Although establishing a definitive correlation between specific genotypes and clinical phenotypes remains challenging, emerging evidence suggests a potential association. This underscores the critical need for further large-scale studies to elucidate this relationship. Given the current understanding of the pathophysiological mechanisms associated with XLP1, specific treatments to normalize SAP expression and restore immune tolerance in XLP1 patients play an important role. In addition to the necessity for long-term studies to verify the efficacy and safety of hematopoietic stem cell transplantation (HSCT), gene therapies currently under development, along with other emerging treatments, exhibit substantial promise for future clinical applications.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1620327","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:20:42Z","timestamp":1749705642000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["X-linked lymphoproliferative disease type 1: a clinical and genetic update"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiaxun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpeng","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(75)92004-8","article-title":"X-linked recessive progressive combined variable immunodeficiency (Duncan's disease)","volume":"1","author":"Purtilo","year":"1975","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(83)90139-1","article-title":"Immunopathology of X-linked lymphoproliferative syndrome","volume":"4","author":"Purtilo","year":"1983","journal-title":"Immunol Today"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2005.00230.x","article-title":"Molecular and cellular pathogenesis of X-linked lymphoproliferative disease","volume":"203","author":"Nichols","year":"2005","journal-title":"Immunol Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-298372","article-title":"Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1\/SAP deficiency) versus type 2 (XLP-2\/XIAP deficiency)","volume":"117","author":"Schmid","year":"2011","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: Biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/26683","article-title":"The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM","volume":"395","author":"Sayos","year":"1998","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-014-0083-7","article-title":"XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP","volume":"34","author":"Tangye","year":"2014","journal-title":"J Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/ncb920","article-title":"SAP couples Fyn to SLAM immune receptors","volume":"5","author":"Chan","year":"2003","journal-title":"Nat Cell Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ncb919","article-title":"Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulation","volume":"5","author":"Latour","year":"2003","journal-title":"Nat Cell Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.691024","article-title":"X-Linked Lymphoproliferative Disease Mimicking Multisystem Inflammatory Syndrome in Children-A Case Report","volume":"9","author":"Prader","year":"2021","journal-title":"Front Pediatr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.4.1268","article-title":"SH2D1A mutations in Japanese males with severe Epstein-Barr virus\u2013associated illnesses","volume":"98","author":"Sumazaki","year":"2001","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000531296","article-title":"X-Linked Lymphoproliferative Syndrome: A Spectrum of Clinical and Immunological Profile and Novel Pathogenic Variants from Chandigarh, India","volume":"185","author":"Jindal","year":"2024","journal-title":"Int Arch Allergy Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.747738","article-title":"Case Report: Meningoencephalitis With Thrombotic Occlusive Vasculopathy in a Young EBV-Na\u00efve Boy Is Associated With a Novel SH2D1A Mutation","volume":"12","author":"Steininger","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1873","article-title":"Exon skipping caused by a complex structural variation in SH2D1A resulted in X-linked lymphoproliferative syndrome type 1","volume":"10","author":"Wu","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.812590","article-title":"Case Report: Novel Splicing Variant in SH2D1A in a Patient With X-Linked Lymphoproliferative Syndrome Type 1","volume":"10","author":"Kwon","year":"2022","journal-title":"Front Pediatr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052097","article-title":"SAP regulates T cell-mediated help for humoral immunity by a mechanism distinct from cytokine regulation","volume":"203","author":"Cannons","year":"2006","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/bjh.17638","article-title":"Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes","volume":"196","author":"El-Mallawany","year":"2022","journal-title":"Br J Haematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10875-024-01701-0","article-title":"Single-Cell Transcriptomic Analysis of Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis","volume":"44","author":"Suzuki","year":"2024","journal-title":"J Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2016.00047","article-title":"Hemophagocytic Lymphohistiocytosis in Children: Pathogenesis and Treatment","volume":"4","author":"Ishii","year":"2016","journal-title":"Front Pediatr"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO)","volume":"66","author":"Jordan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2010-06-284935","article-title":"X-linked lymphoproliferative disease due to SAP\/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease","volume":"117","author":"Booth","year":"2011","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1007\/s13312-020-2043-z","article-title":"X-linked Lymphoproliferative Disease (XLP1) Presenting as Non-Epstein Barr Virus (EBV)-Related Hemophagocytic Lymphohistiocytosis (HLH)","volume":"57","author":"Loganathan","year":"2020","journal-title":"Indian Pediatr"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1038\/cti.2015.1","article-title":"Infectious mononucleosis","volume":"4","author":"Balfour","year":"2015","journal-title":"Clin Transl Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3345\/kjp.2011.54.10.409","article-title":"Clinical features of Epstein-Barr virus-associated infectious mononucleosis in hospitalized Korean children","volume":"54","author":"Son","year":"2011","journal-title":"Korean J Pediatr"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa601","article-title":"The Nature and Clinical Significance of Atypical Mononuclear Cells in Infectious Mononucleosis Caused by the Epstein-Barr Virus in Children","volume":"223","author":"Fedyanina","year":"2021","journal-title":"J Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275909","article-title":"X-linked lymphoproliferative syndromes: brothers or distant cousins","volume":"116","author":"Filipovich","year":"2010","journal-title":"Blood."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00666","article-title":"X-Linked Lymphoproliferative Disease Type 1: A Clinical and Molecular Perspective","volume":"9","author":"Panchal","year":"2018","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03851.x","article-title":"X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective","volume":"119","author":"Gaspar","year":"2002","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1370991","article-title":"Case report: EBV-related eye orbits and sinuses lymphohistiocytic infiltration responsive to rituximab in a patient with X lymphoproliferative syndrome type 1","volume":"15","author":"Giardino","year":"2024","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1323836","article-title":"Fatal EBV infection and variable clinical manifestations in an XLP-1 pedigree - rapid diagnosis of primary immunodeficiencies may save lives","volume":"224","author":"Sperl","year":"2012","journal-title":"Klin Padiatr"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2012.01282.x","article-title":"Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis","volume":"23","author":"Kanegane","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2016.06.005","article-title":"Variable clinical phenotypes of X-linked lymphoproliferative syndrome in China: Report of five cases with three novel mutations and review of the literature","volume":"77","author":"Jin","year":"2016","journal-title":"Hum Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.6040\/j.issn.1671-7554.0.2021.0818","article-title":"A case report of rare adult XLP-1","volume":"60","author":"Sun","year":"2022","journal-title":"J Shandong Univ (Medical Sci Edition)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.6040\/j.issn.1671-7554.0.2023.0527","article-title":"One adult patient with et\u00a0al. X-linked lymphoproliferative disorder","volume":"61","author":"Wu","year":"2023","journal-title":"J Shandong Univ (Medical Sci Edition)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlz018","article-title":"X-Linked Lymphoproliferative Syndrome Presenting as Adult-Onset Multi-Infarct Dementia","volume":"78","author":"Blackburn","year":"2019","journal-title":"J Neuropathol Exp Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03810-y","article-title":"A new SH2D1A mutation in a female adult XLP disease with hemophagocytic lymphohistiocytosis and NK-cell leukemia","volume":"98","author":"Liang","year":"2019","journal-title":"Ann Hematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00649-w","article-title":"Different Phenotypic Presentations of X-Linked Lymphoproliferative Disease in Siblings with Identical Mutations","volume":"39","author":"Nademi","year":"2019","journal-title":"J Clin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20112391","article-title":"Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus","volume":"209","author":"Palendira","year":"2012","journal-title":"J Exp Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/2424","article-title":"Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene","volume":"20","author":"Coffey","year":"1998","journal-title":"Nat Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200006)30:6<1691::AID-IMMU1691>3.0.CO;2-K","article-title":"Diagnosis of X-linked lymphoproliferative disease by analysis of SLAM-associated protein expression","volume":"30","author":"Gilmour","year":"2000","journal-title":"Eur J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.018","article-title":"The SLAM family receptors: Potential therapeutic targets for inflammatory and autoimmune diseases","volume":"17","author":"Dragovich","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.coi.2015.11.003","article-title":"SLAM family receptors in normal immunity and immune pathologies","volume":"38","author":"Wu","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jaci.2022.06.021","article-title":"Allosteric inhibition of SHP2 rescues functional T-cell abnormalities in SAP deficiency","volume":"150","author":"Panchal","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nature07345","article-title":"SAP-controlled T-B cell interactions underlie germinal centre formation","volume":"455","author":"Qi","year":"2008","journal-title":"Nature."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101400","article-title":"Follicular helper CD4 T cells (TFH)","volume":"29","author":"Crotty","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-120419-022408","article-title":"Germinal Centers","volume":"40","author":"Victora","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601218","article-title":"Sensitivity to Restimulation-Induced Cell Death Is Linked to Glycolytic Metabolism in Human T Cells","volume":"198","author":"Larsen","year":"2017","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39518","article-title":"Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency","volume":"119","author":"Snow","year":"2009","journal-title":"J Clin Invest"},{"key":"B49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cellimm.2018.02.007","article-title":"FOXP3 renders activated human regulatory T cells resistant to restimulation-induced cell death by suppressing SAP expression","volume":"327","author":"Katz","year":"2018","journal-title":"Cell Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654839","article-title":"SLAM Associated Protein Signaling in T Cells: Tilting the Balance Toward Autoimmunity","volume":"12","author":"Gartshteyn","year":"2021","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1710437115","article-title":"Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor","volume":"115","author":"Peled","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1001187","article-title":"Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP","volume":"9","author":"Palendira","year":"2011","journal-title":"PloS Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/v14112372","article-title":"How EBV Infects: The Tropism and Underlying Molecular Mechanism for Viral Infection","volume":"14","author":"Bu","year":"2022","journal-title":"Viruses."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20112401","article-title":"Primary Epstein-Barr virus infection does not erode preexisting CD8\u207a T cell memory in humans","volume":"209","author":"Odumade","year":"2012","journal-title":"J Exp Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2525","article-title":"Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection","volume":"103","author":"Malbran","year":"2004","journal-title":"Blood."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1406","article-title":"Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome","volume":"106","author":"Chuang","year":"2005","journal-title":"Blood."},{"key":"B57","article-title":"Positive correlation between VCA-IgM and Th1\/Th2 immunocytokines in children with infectious mononucleosis","volume":"14","author":"Yang","year":"2022","journal-title":"Am J Transl Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115976","article-title":"Polysaccharides regulate Th1\/Th2 balance: A new strategy for tumor immunotherapy","volume":"170","author":"Shang","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1126\/science.6158759","article-title":"Deficient natural killer cell activity in x-linked lymphoproliferative syndrome","volume":"210","author":"Sullivan","year":"1980","journal-title":"Science."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.023","article-title":"The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells","volume":"36","author":"Dong","year":"2012","journal-title":"Immunity."},{"key":"B61","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.clim.2018.10.011","article-title":"SLAM family receptors in natural killer cells - Mediators of adhesion, activation and inhibition via cis and trans interactions","volume":"204","author":"Claus","year":"2019","journal-title":"Clin Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.immuni.2016.07.013","article-title":"The Self-Specific Activation Receptor SLAM Family Is Critical for NK Cell Education","volume":"45","author":"Chen","year":"2016","journal-title":"Immunity."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ai.2019.11.006","article-title":"Regulation of MHC class I-independent NK cell education by SLAM family receptors","volume":"145","author":"Chen","year":"2020","journal-title":"Adv Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132038","article-title":"EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase C\u03b3, Ca++, and Erk, leading to granule polarization","volume":"211","author":"P\u00e9rez-Quintero","year":"2014","journal-title":"J Exp Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0222-4","article-title":"NK cell recognition of hematopoietic cells by SLAM-SAP families","volume":"16","author":"Chen","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444562","article-title":"WhatSAP - 2B4 sends mixed messages in the absence of SAP","volume":"44","author":"Watzl","year":"2014","journal-title":"Eur J Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200011)30:11<3309::AID-IMMU3309>3.0.CO;2-3","article-title":"Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity","volume":"30","author":"Nakajima","year":"2000","journal-title":"Eur J Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nri3370","article-title":"Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution","volume":"13","author":"Parham","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646885","article-title":"Inhibitory 2B4 contributes to NK cell education and immunological derangements in XLP1 patients","volume":"47","author":"Meazza","year":"2017","journal-title":"Eur J Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301629","article-title":"CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response","volume":"191","author":"Abbott","year":"2013","journal-title":"J Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1177\/17534259211001512","article-title":"Human NK cells: From development to effector functions","volume":"27","author":"Perera Molligoda Arachchige","year":"2021","journal-title":"Innate Immun"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.3.235","article-title":"NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease","volume":"194","author":"Bottino","year":"2001","journal-title":"J Exp Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.10.022","article-title":"2B4 dysfunction in XLP1 NK cells: More than inability to control EBV infection","volume":"204","author":"Pende","year":"2019","journal-title":"Clin Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.160010","article-title":"Modulation of natural killer cell functions by interactions between 2B4 and CD48 in cis and in trans","volume":"6","author":"Claus","year":"2016","journal-title":"Open Biol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.4.2311","article-title":"Differential requirement for the SAP-Fyn interaction during NK T cell development and function","volume":"181","author":"Nunez-Cruz","year":"2008","journal-title":"J Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1084\/jem.20042432","article-title":"Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product","volume":"201","author":"Pasquier","year":"2005","journal-title":"J Exp Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18159","article-title":"Patients with XLP type 1 have variable numbers of NKT cells","volume":"198","author":"Ralph","year":"2022","journal-title":"Br J Haematol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161312","article-title":"Dissection of SAP-dependent and SAP-independent SLAM family signaling in NKT cell development and humoral immunity","volume":"214","author":"Chen","year":"2017","journal-title":"J Exp Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030951","article-title":"Potential pathogenic mechanism of type 1 X-linked lymphoproliferative syndrome caused by a mutation of SH2D1A gene in an infant: A case report","volume":"101","author":"Wang","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase \u03b4 syndrome: A large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2022.06.004","article-title":"Fatal X-linked lymphoproliferative disease type 1-associated limbic encephalitis with positive anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antibody","volume":"44","author":"Ochiai","year":"2022","journal-title":"Brain Dev"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1086\/652752","article-title":"Clinical significance of cloned expansion and CD5 down-regulation in Epstein-Barr Virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis","volume":"201","author":"Toga","year":"2010","journal-title":"J Infect Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jaci.2014.04.043","article-title":"Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis","volume":"134","author":"Meazza","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192262","article-title":"Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection","volume":"217","author":"Fournier","year":"2020","journal-title":"J Exp Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03786-0","article-title":"Highly sensitive detection of Epstein-Barr virus-infected cells by EBER flow FISH","volume":"120","author":"Tomomasa","year":"2024","journal-title":"Int J Hematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/nm1189","article-title":"Regulation of NKT cell development by SAP, the protein defective in XLP","volume":"11","author":"Nichols","year":"2005","journal-title":"Nat Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2010.08.010","article-title":"Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency","volume":"362","author":"Marsh","year":"2010","journal-title":"J Immunol Methods"},{"key":"B90","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12881-018-0576-y","article-title":"Identification of a novel nonsense mutation in SH2D1A in a patient with X-linked lymphoproliferative syndrome type 1: a case report","volume":"19","author":"Lyu","year":"2018","journal-title":"BMC Med Genet"},{"key":"B91","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clim.2018.12.016","article-title":"Management of XLP-1 and ITK deficiency: The challenges posed by PID with an unpredictable spectrum of disease manifestations","volume":"198","author":"Shadur","year":"2019","journal-title":"Clin Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxab034","article-title":"Droplet digital PCR for identifying copy number variations in patients with primary immunodeficiency disorders","volume":"207","author":"Woon","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3705376","article-title":"EBV Infection in XLP1 Manifested Solely by Behavioral Aggression and Effective Treatment Using Rituximab","volume":"2018","author":"Korah-Sedgwick","year":"2018","journal-title":"Case Rep Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol","volume":"118","author":"Trottestam","year":"2011","journal-title":"Blood."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis","volume":"12","author":"Keenan","year":"2021","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.05.031","article-title":"Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society","volume":"6","author":"Ehl","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"Blood."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017007526","article-title":"Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis","volume":"1","author":"Broglie","year":"2017","journal-title":"Blood Adv"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.253781","article-title":"A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis","volume":"106","author":"Zhang","year":"2021","journal-title":"Haematologica."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02936-4","article-title":"Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children","volume":"112","author":"Wei","year":"2020","journal-title":"Int J Hematol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222471","article-title":"Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica."},{"key":"B103","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.seminhematol.2018.07.006","article-title":"Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH","volume":"57","author":"Wang","year":"2020","journal-title":"Semin Hematol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28071","article-title":"Successful remission induction in refractory familial hemophagocytic lymphohistiocytosis with ruxolitinib as a bridge to hematopoietic stem cell transplantation","volume":"67","author":"Ramanan","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0577-2","article-title":"Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis","volume":"55","author":"Zhao","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.11.001","article-title":"Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States","volume":"22","author":"Apperley","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B107","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10875-020-00888-2","article-title":"Experience with a Reduced Toxicity Allogeneic Transplant Regimen for Non-CGD Primary Immune Deficiencies Requiring Myeloablation","volume":"41","author":"Chandra","year":"2021","journal-title":"J Clin Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8841571","article-title":"The Natural History of X-Linked Lymphoproliferative Disease (XLP1): Lessons from a Long-Term Survivor","volume":"2020","author":"Jiang","year":"2020","journal-title":"Case Rep Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.108993","article-title":"Preemptive hematopoietic cell transplantation for asymptomatic patients with X-linked lymphoproliferative syndrome type 1","volume":"237","author":"Tomomasa","year":"2022","journal-title":"Clin Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"321ra7","DOI":"10.1126\/scitranslmed.aad1565","article-title":"Inhibition of diacylglycerol kinase \u03b1 restores restimulation-induced cell death and reduces immunopathology in XLP-1","volume":"8","author":"Ruffo","year":"2016","journal-title":"Sci Transl Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.12.061","article-title":"Identification of a novel DGK\u03b1 inhibitor for XLP-1 therapy by virtual screening","volume":"164","author":"Velnati","year":"2019","journal-title":"Eur J Med Chem"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-238832","article-title":"Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets","volume":"116","author":"Hislop","year":"2010","journal-title":"Blood."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28329","article-title":"Natural killer T cell strategies to combat Epstein-Barr virus infection","volume":"3","author":"Priatel","year":"2014","journal-title":"Oncoimmunology."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk4898","article-title":"A metabolic dependency of EBV can be targeted to hinder B cell transformation","volume":"385","author":"M\u00fcller-Durovic","year":"2024","journal-title":"Science"},{"key":"B115","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jaci.2018.02.053","article-title":"Transfer of gene-corrected T cells corrects humoral and cytotoxic defects in patients with X-linked lymphoproliferative disease","volume":"142","author":"Panchal","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2022.828489","article-title":"Genome Editing With TALEN, CRISPR-Cas9 and CRISPR-Cas12a in Combination With AAV6 Homology Donor Restores T Cell Function for XLP","volume":"4","author":"Houghton","year":"2022","journal-title":"Front Genome Ed"},{"key":"B117","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat Genet"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1227231","article-title":"Editorial: Immunogenicity and toxicity of AAV gene therapy","volume":"14","author":"Bradbury","year":"2023","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.stem.2018.12.011","article-title":"Organoid-Induced Differentiation of Conventional T Cells from Human Pluripotent Stem Cells","volume":"24","author":"Montel-Hagen","year":"2019","journal-title":"Cell Stem Cell"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101323","article-title":"Lentiviral vectors for precise expression to treat X-linked lymphoproliferative disease","volume":"32","author":"Ayoub","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-04912-6","article-title":"Immune-mediated cytopenias (IMCs) after HSCT for pediatric non-malignant disorders: epidemiology, risk factors, pathogenesis, and treatment","volume":"182","author":"Spadea","year":"2023","journal-title":"Eur J Pediatr"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1620327\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:20:45Z","timestamp":1749705645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1620327\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":121,"alternative-id":["10.3389\/fimmu.2025.1620327"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1620327","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"article-number":"1620327"}}